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The serine protease high-temperature requirement protein
A1 (HtrA1) is associated with protein-misfolding disorders
such as Alzheimer’s disease and transforming growth factor
–induced protein (TGFBIp)–linked corneal dystrophy. In this
study, using several biochemical and biophysical approaches,
including recombinant protein expression, LC-MS/MS and 2DE
analyses, and thioflavin T (ThT) fluorescence assays for amyloid
fibril detection, and FTIR assays, we investigated the role of
HtrA1 both in normal TGFBIp turnover and in corneal amyloid
formation. We show that HtrA1 can cleave WT TGFBIp but
prefers amyloidogenic variants. Corneal TGFBIp is extensively
processed in healthy people, resulting in C-terminal degrada-
tion products spanning the FAS1-4 domain of TGFBIp. We
show here that HtrA1 cleaves the WT FAS1-4 domain only inef-
ficiently, whereas the amyloidogenic FAS1-4 mutations trans-
form this domain into a considerably better HTRA1 substrate.
Moreover, HtrA1 cleavage of the mutant FAS1-4 domains gen-
erated peptides capable of forming in vitro amyloid aggregates.
Significantly, these peptides have been previously identified in
amyloid deposits in vivo, supporting the idea that HtrA1 is a
causative agent for TGFBIp-associated amyloidosis in corneal
dystrophy. In summary, our results indicate that TGFBIp is an
HtrA1 substrate and that some mutations in the gene encoding
TGFBIp cause aberrant HtrA1-mediated processing that results
in amyloidogenesis in corneal dystrophies.
Transforming growth factor beta-induced protein (TGFBIp,
UniProt Q15582) is one of the most abundant proteins in the
human cornea (1). In addition to the full-length protein, trun-
cated TGFBIp fragments are observed after immunoblotting,
most likely as a result of proteolysis. The smallest fragment
observed comprises the C-terminal domain of TGFBIp, known
as the FAS1-4 domain (2). The physiological role of TGFBIp in
the cornea is not understood but may involve extracellular
matrix cell adhesion involving several integrin-binding motifs
(3, 4) and a C-terminal RGD integrin-binding motif. In addi-
tion, TGFBIp binds covalently to type XII collagen via a reduc-
ible bond (5). Knocking out TGFBIp in mice showed little effect
on corneal integrity and mouse behavior in general (6). TGFBIp
is involved in the pathophysiology of the amyloid corneal dis-
ease lattice corneal dystrophy (LCD)3 and amorphous granular
corneal dystrophy (GCD). For a review, see Ref. 7. These dis-
eases are characterized by TGFBIp misfolding and/or aggrega-
tion and the accumulation of insoluble protein deposits leading
to visual impairment. The misfolding and/or aggregation of
TGFBIp can be caused by 70 different mutations (8) mainly
situated in the first FAS1 domain (FAS1-1) or in the fourth
FAS1 domain (FAS1-4) of TGFBIp. Several of these mutations
affect the thermodynamic stability of the protein (9 –11). An
increase in thermodynamic stability has been linked to muta-
tions associated with GCD that cause amorphous aggregates,
whereas a decrease in thermodynamic stability has been linked
to mutations associated with LCD that cause amyloid deposits.
Mass spectrometry analyses of microdissected amyloid depos-
its from three different TGFBIp genotypes (A546D, A546D/
P551Q, and V624M) of LCD showed elevated levels of peptides
derived from the Tyr-571–Arg-588 amyloidogenic polypeptide
region of FAS1-4. In addition, an increase in proteolytic suscep-
tibility was observed in a region including residues Phe-515–
Arg-533, located in the N-terminal of FAS1-4, compared with
normal corneal TGFBIp (12–14). Deposits derived from GCD
cases (13, 15) do not share the LCD characteristics, suggesting
that distinct mechanisms are involved in these two types of
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corneal dystrophies. Intriguingly, protein deposits from all ana-
lyzed cases of LCD show accumulation of the serine protease
high-temperature requirement A1 (HtrA1, UniProt Q92743,
and MEROPS S01.277), possibly implicating this protease in
the development of amyloid deposition in LCD (12). In con-
trast, HtrA1 is absent in the amorphous nonamyloid aggregates
in GCD (13, 15). HtrA1 is a 51-kDa nonglycosylated serine pro-
tease that exists as a trimeric catalytic unit. It contains an N-ter-
minal IGFBP-like domain, and a Kazal-like domain that can be
removed by redox-mediated autolysis (16) and a C-terminal
PDZ domain, that potentially may be involved in its association
with fibrillar deposits (17). HtrA1 is expressed in the healthy
cornea (1), and although its activation mechanism (18) and
exact role are unclear, the homology to its bacterial counter-
part, DegP, suggests that HtrA1 is involved in protein quality
control (19, 20). HtrA1 is associated with amyloid deposits of
immunoglobulin light chain amyloidosis (21), drusen deposits
in age-related macular degeneration (22), and Alzheimer’s dis-
ease (23). Concerning Alzheimer’s disease, HtrA1 likely plays a
role in amyloid protein turnover because the protease can
degrade both monomeric and aggregated versions of several
amyloid proteins (23, 24) and leads to the disintegration of amy-
loid fibrils (17).
In this study, the role of HtrA1 in the pathophysiology of
TGFBI-linked corneal dystrophy was investigated by examin-
ing the ability of HtrA1 to cleave WT TGFBIp and seven
mutants as well as WT FAS1-4 and six mutants. The TGFBIp
isoforms included the two major LCD and GCD phenotypes
caused by mutations in either the FAS1-1 or the FAS1-4
domain of TGFBIp. Our data show that TGFBIp may be the
victim of counterproductive proteolysis, as HtrA1 attempts to
degrade misfolded protein and inadvertently causes amyloid
formation. We furthermore propose a model on how corneal
proteostasis and the dual aggregation propensity of TGFBIp
can lead to either the amorphous aggregates seen in GCD or the
amyloid deposits observed in LCD.
Results
HtrA1 cleaves full-length TGFBIp protein in vitro
We expressed and purified seven mutant TGFBIp isoforms
in addition to the WT protein (Fig. 1A). The seven TGFBIp
mutants included the mutations R124C, R124H, and R124L,
which are situated in the FAS1-1 domain of TGFBIp and are
frequently observed in vivo, and the biologically relevant muta-
tions A546D, A546D/P551Q, A546T, and R555W, which are
located in the FAS1-4 domain of TGFBIp. Except for the R124L
and A546T isoforms, we have previously characterized TGFBIp
protein deposits of the remaining five mutant TGFBIp isoforms
in corneal tissues (12–15, 25) of patients with LCD or GCD.
This information allows us to compare the in vitro data pre-
sented herein to previously published in vivo data. The purified
recombinant TGFBIp protein migrated as a double band when
analyzed by SDS-PAGE (Fig. 1B) for all isoforms except for the
R124H mutant. We used a single reaction monitoring MS assay
(LC-SRM-MS) to delineate the nature of this double band. By
monitoring a tryptic peptide at each terminal of TGFBIp, we
identified the lower band as a C-terminally truncated TGFBIp
isoform (Fig. 1C). The R124H mutant appears only as the C-ter-
minally truncated protein.
Because HtrA1 accumulates in LCD TGFBIp deposits in
vivo, we tested its activity toward the eight TGFBIp isoforms
using a titration series of HtrA1 (Fig. 1). The eight TGFBIp
isoforms were ranked from least to most susceptible to
proteolysis as follows: R124HWTR555WA546D/P551Q
R124CA546DA546TR124L (Fig. 1D). The results revealed
that the GCD mutants R124H and R555W were similarly or
even more resistant to proteolysis than WT TGFBIp. The
remaining mutant isoforms, all representing LCD except the
R124L mutant, which causes Reis-Bücklers corneal dystro-
phy (RBCD), were more susceptible to proteolysis. Of note,
HtrA1 showed a preference for full-length TGFBIp over the
C-terminal truncated isoform and appeared to cause a shift
from the upper band to the lower band over time (Fig. 1B).
Interestingly, the R124H mutant appeared as only one band
and thus seemed resistant to HtrA1 proteolysis. Whether the
apparent proteolytic resistance is a consequence of the
R124H mutation altering the structure or binding of HtrA1
to the C-terminal is required for the further proteolysis
of TGFBIp is unknown. Together, these data support the
idea that HtrA1 is involved in the natural turnover of TGF-
BIp in the healthy cornea as WT recombinant protein is
processed and that introducing a mutation into TGFBIp
affects its turnover rate.
FAS1-4 mutations associated with LCD lead to HtrA1-
mediated degradation
The normal metabolism of corneal TGFBIp occurs by N-ter-
minal trimming and produces fragments containing the C-ter-
minal FAS1-4 domain. Therefore, we tested the ability of HtrA1
to cleave the WT FAS1-4 domain and six FAS1-4 mutants (Fig.
2). The double bands seen for the A546D and A546D/P551Q
FAS1-4 domains (Fig. 2A) are, as shown previously (26),
because of deamidations. The deamidations did not affect
HtrA1 specificity and activity because both bands were
degraded to the same extent. HtrA1 titration against the six
mutant FAS1-4 domains separated the mutants into two dis-
tinct groups. One group was resistant to HtrA1 proteolysis
and contained WT and the R555W and R555Q mutations
associated with the nonamyloidogenic phenotypes GCD and
Thiel-Behnke corneal dystrophy (TBCD) (Fig. 2B). The
other group was susceptible to HtrA1 proteolysis and con-
tained the A546T, A546D, A546D/P551Q, and V624M
mutations, all representing the amyloidogenic phenotype
LCD (Fig. 2C). In particular, the two A546D-containing
mutants were markedly more susceptible to proteolysis than
A546T and V624M, which showed similar sensitivity to
proteolysis. The data suggest that the FAS1-4 domain is
not a substrate for HtrA1 in healthy individuals. However,
the destabilizing mutations associated with LCD change
TGFBIp into a substrate for HtrA1.
HtrA1 cleaves near the amyloidogenic region of FAS1-4 in
TGFBIp
We analyzed the HtrA1 digest of FAS1-4 mutants associated
with LCD (A546T, A546D, A546D/P551Q, and V624M) by MS
HtrA1 proteolysis of TGFBIp
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to map the HtrA1 cleavage sites (P1 residue of both the N and C
termini) across the various FAS1-4 mutants (Fig. 3). The
mutants underwent extensive cleavage in two main clusters
located in the peptide regions Phe-515–Ala-525 and Glu-615–
Pro-635. In addition, all amyloidogenic mutants underwent
additional peptide bond cleavage in the region between the two
main proteolytic clusters. These additional cleavage sites lie
near or within the amyloidogenic region of TGFBIp (residues
Tyr-571–Arg-588) located in FAS1-4, and we suggest that
HtrA1 contributes to the development of LCD by generating
amyloidogenic peptides.
HtrA1 proteolysis of LCD-linked FAS1-4 leads to aggregation
We addressed the aggregation propensity of HtrA1-gener-
ated FAS1-4 peptides by incubating monomeric FAS1-4
mutants (A546T, A546D, A546D/P551Q, and V624M) with
HtrA1 for 21 h. After an additional 4 days of sample incubation,
the pellets were separated from the supernatant by centrifuga-
tion. Both fractions were analyzed by LC-MS/MS, and the iden-
tified peptides were binned in 10 –amino acid residue intervals
across the FAS1-4 domain. A similar pattern was apparent for
all amyloidogenic mutant FAS1-4 isoforms (Fig. 4A). The pellet
fractions mainly consisted of peptides spanning the Gly-560 –
Leu-589 region of TGFBIp and, to a lesser extent, the Pro-500 –
Glu-529 region. The supernatant, on the other hand, showed
the highest peptide counts outside the Gly-560 –Leu-589
region (Fig. 4A). Hence, HtrA1 was able to generate TGFBIp
peptides with the propensity to form insoluble aggregates
consisting of peptides derived from the amyloidogenic
region of FAS1-4 in TGFBIp. The number of peptides falling
within the amyloidogenic region of TGFBIp constituted
between 65 and 74% of all peptides identified in the pellet
fraction (Fig. 4B). The highest represented peptide in the
core region varied among genotypes; however, they all
shared the sequence 570-KYHIGDEILV-579 (Fig. 4B).
Therefore, the peptide region Lys-570 –Val-579 appears to
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Figure 1. Full-length TGFBIp is a substrate for HtrA1. A, schematic representation of TGFBIp and its domain structure. Disease-linked mutations investigated
in this study are marked along with the phenotype associated with the mutation. B, SDS-PAGE followed by immunoblotting of the HtrA1 titration series against
WT and mutant full-length TGFBIp. C, SRM-LC-MS analysis of TGFBIp terminal peptides in the two bands observed by SDS-PAGE. The ratios (lower/upper band
ratio) of the N-terminal and C-terminal peptides showed a close to 1:1 ratio for the N-terminal peptide, whereas the C-terminal peptide showed a low ratio
across all genotypes, suggesting a C-terminal truncation in the lower band. D, densitometry of the HtrA1 titrations showed that the R124L mutation associated
with RBCD and that mutations associated with LCD (R124C, A546T, A546D) increased in vitro TGFBIp turnover, whereas the LCD mutation A546D/P551Q
showed a similar degradation trend as WT protein. The R555W mutation associated with GCD had no influence on the TGFBIp turnover rate, whereas the R124H
mutation also classified as GCD resulted in increased proteolytic resistance against HtrA1. In general, HtrA1 showed a preference for full-length TGFBIp, causing
a shift toward the C-terminally truncated TGFBIp variant before further processing. Experiments were performed in technical triplicate, and S.D. error bars are
depicted for each titration point.
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be essential for the progression of LCD if the disease is
caused by mutations in the FAS1-4 domain.
HtrA1-driven aggregates are amyloid in nature
HtrA1-generated fibrils were verified to be amyloid struc-
tures based on thioflavin T (ThT) fluorescence, FTIR, and
transmission EM (TEM) (Fig. 5). FAS1-4 mutants were digested
for 21 h with HtrA1, followed by 4 days of incubation. Increased
ThT fluorescence as a function of time was observed for all four
LCD-linked FAS1-4 variants in the presence of HtrA1, whereas
ThT fluorescence was considerably reduced for the FAS1-4
variant alone, where only the A546D and A546D/P551Q
mutants showed a slight fluorescence signal (Fig. 5A). The sam-
ples were further analyzed by FTIR spectroscopy, which
showed a shift for the undigested FAS1-4 mutants from 1651–
1653 cm1 to 1627–1630 cm1, values characteristic of -sheet
and -amyloid-sheet, respectively (27), upon incubation with
HtrA1 (Fig. 5B). The undigested A546D/P551Q mutant dis-
played both peaks, which could explain the slight ThT fluores-
cence signal observed for this mutant. Only the amyloid peak
was observed for the digested A546D/P551Q mutant. Finally,
the TEM micrographs showed elongated fibrils for FAS1-4
samples incubated with HtrA1, whereas nonfibrillar aggregates
were observed for nonprotease-treated FAS1-4 mutants. The
A546D and A546D/P551Q samples contained larger nonlinear
aggregates than did A546T and V624M (Fig. 5C), which most
likely accounted for the amyloid signatures observed in the ThT
and FTIR experiments.
HtrA1 is expressed throughout the healthy human cornea
To address whether HtrA1 is ubiquitously expressed
throughout the stroma in healthy human corneas or accumu-
lates only in amyloid deposits in patients’ tissues, human cor-
neal buttons were cut into 50 m sections from the epithelium
toward the endothelium. Approximately every second tissue
section was subjected to SDS-PAGE and immunoblotting
against HtrA1 (Fig. 6). The blots showed HtrA1 to be present
throughout the corneal stroma, suggesting that HtrA1 is
involved in normal corneal proteostasis and not induced only
by LCD development.
LCD tissue contains fewer FAS1-4 degradation products
The in vivo processing of mutant TGFBIp was examined by
visualizing the TGFBIp degradation patterns in patient tissue
(A546D and V624M) and normal corneal tissue by 2D gel elec-
trophoresis (2DE) and immunoblotting (Fig. 7). In the normal
cornea, a characteristic degradation pattern of TGFBIp is
observed as a consequence of N-terminal trimming; accord-
ingly, all observed degradation products contain the FAS1-4
domain (2). Interestingly, A546D and V624M patient tissue had
a reduced amount of degradation products, and the character-
istic processing pattern was nearly undetectable. Notably, the
antiserum recognizes only the FAS1-4 domain of TGFBIp;
therefore, the observed TGFBIp degradation products, partic-
ularly in normal tissue, contained the FAS1-4 domain. As the
FAS1-4 domain becomes a substrate for HtrA1 upon the intro-
duction of a mutation associated with LCD (Fig. 2), the 2DE
immunoblot data implied that TGFBIp degradation products
spanning the FAS1-4 domain are consumed more rapidly by
HtrA1, thus generating amyloidogenic core peptides situated in
the FAS1-4 domain.
Discussion
TGFBIp is a substrate for HtrA1
Several extracellular proteins have been characterized as in
vitro or in vivo substrates for HtrA1, such as fibronectin, fibro-
modulin, biglycan, aggrecan, and fibulin-5 (28), and our in vitro
data add TGFBIp to this list of substrates. We showed that
HtrA1 was capable of cleaving WT TGFBIp to a minor extent,
and, except for R124H, all remaining TGFBIp mutants were
processed to the same or a higher degree than WT protein, with
the highest preferences for mutant isoforms associated with the
RBCD and LCD phenotypes (Fig. 1). Previous results from our
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Figure 2. Mutation in FAS1-4 dictates the turnover rate. A, SDS-PAGE of
the HtrA1 titration series against the WT and mutant FAS1-4 domains of
TGFBIp. B and C, densitometric analyses showed (B) proteolytic resistance
against HtrA1 by mutants associated with the nonamyloidogenic pheno-
types GCD (R555W) and Thiel-Behnke corneal dystrophy (TBCD) (R555Q); (C)
proteolytic sensitivity of mutations giving rise to LCD. WT FAS1-4 was mini-
mally processed by HtrA1. Experiments were performed in technical tripli-
cate, and S.D. error bars are depicted for each titration point.
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group have shown extensive corneal TGFBIp processing in
healthy tissue, of which the smallest degradation product was
FAS1-4 (2). As a model for the FAS1-4-containing degradation
product and to assess its potential role as an HtrA1 substrate, we
recombinantly expressed the FAS1-4 domain and subjected it to
HtrA1-mediated degradation. Proteolysis of the WT and mutant
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Figure 3. FAS1-4 mutations cause alternative HtrA1 degradation. The introduction of an in vivo relevant mutation in the FAS1 domain of TGFBIp influenced
its degradation by HtrA1. The major cleavage sites, represented by more than eight spectra in the LC-MS/MS analysis, became more abundant in mutant
proteins associated with the LCD phenotype (A546T, A546D, A546D/P551Q, and V624M). Cleavage sites appeared in and near the amyloidogenic 571–588
region in FAS1-4. Samples were analyzed in technical triplicate.
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EndStart
566 579 23 5% 7% ANILKYHIGDEILV
566 587 16 3% 5% ANILKYHIGDEILVSGGIGALV
566 589 36 8% 11% ANILKYHIGDEILVSGGIGALVRL
570 587 41 9% 12% KYHIGDEILVSGGIGALV
570 589 48 10% 14% KYHIGDEILVSGGIGALVRL
570 590 18 4% 5% KYHIGDEILVSGGIGALVRLK
570 592 20 4% 6% KYHIGDEILVSGGIGALVRLKSL
570 599 29 6% 9% KYHIGDEILVSGGIGALVRLKSLQGDKLEV
Count % of total % of core region Sequence
% core peptides of total peptides          74%
A546T FAS1-4
EndStart
566 579 30 10% 14% ANILKYHIGDEILV
566 589 16 5%  8% ANILKYHIGDEILVSGGIGALVRL
570 587 27 9% 13% KYHIGDEILVSGGIGALV
570 589 37 12% 17% KYHIGDEILVSGGIGALVRL
570 592 13 4% 6% KYHIGDEILVSGGIGALVRLKSL
Count % of total % of core region Sequence
% core peptides of total peptides          71%
A546D FAS1-4
EndStart
566 579 41 15% 23% ANILKYHIGDEILV
570 587 10 4% 6% KYHIGDEILVSGGIGALV
570 592 14 5% 8% KYHIGDEILVSGGIGALVRLKSL
570 599 16 6% 9% KYHIGDEILVSGGIGALVRLKSLQGDKLEV
Count % of total % of core region Sequence
% core peptides of total peptides          65%
A546D/P551Q FAS1-4
EndStart
570 587 41 9% 12% KYHIGDEILVSGGIGALV
570 589 48 10% 14% KYHIGDEILVSGGIGALVRL
570 590 18 4% 5% KYHIGDEILVSGGIGALVRLK
570 592 20 4% 6% KYHIGDEILVSGGIGALVRLKSL
Count % of total % of core region Sequence
% core peptides of total peptides          69%
V624M FAS1-4
B
Figure 4. HtrA1-generated FAS1-4 fibrils correlate with in vivo findings. A, the LCD-linked mutant FAS1-4 was incubated with HtrA1, and the degradation
products were able to form fibrils. The LC-MS/MS analysis of the pellet and supernatant showed the accumulation of peptides spanning the in vivo observed
amyloidogenic region (Arg-571–Tyr-588) situated in FAS1-4 of TGFBIp. B, peptides spanning the amyloidogenic region constituted between 65 and 74% of the fibril
matter, mostly represented by four to eight polypeptides. Start and End define the first and last residue number of the observed peptide. Count displays the total
numberofobservedpeptides.% of totalrepresentsthepercentageofapeptidewithrespecttoall identifiedpeptides,whereas % of core regionrepresentsthepercentageof a
peptide with respect only to peptides falling within the amyloidogenic region of FAS1-4. Sequence displays the amino acid sequence of the observed peptide.
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FAS1-4 domains indeed showed that HtrA1 preferentially
degraded FAS1-4 carrying a mutation associated with the LCD
phenotype (Fig. 2). In contrast, WT FAS1-4 was a poor substrate
for HtrA1 (Fig. 2), and the physiological involvement of HtrA1 in
processing major TGFBIp degradation products containing the
FAS1-4 domain is likely negligible. Collectively, our in vitro data
support a role for HtrA1 in the turnover of disease-associated full-
length TGFBIp. Mutations change FAS1-4 into suitable substrates
for HtrA1 and thereby enable the aberrant processing of TGFBIp,
observed in corneal tissue from LCD patients (Fig. 7).
TGFBIp and HtrA1 are both expressed throughout the corneal
stroma
We have previously shown that the major fraction of corneal
mouse TGFBIp originated from the corneal epithelium (6).
Furthermore, quantification showed abundant HtrA1 protein
in the corneal proteome of the endothelial layer, including
Descemet’s membrane (1). We speculate that TGFBIp migrates
from the epithelium toward the endothelium, where it encoun-
ters HtrA1 secreted from the endothelium. Our data show that
HtrA1 is expressed throughout the stroma of normal corneas
(Fig. 6). This information suggests the possibility that LCD-
linked mutant TGFBIp is immediately exposed to HtrA1-me-
diated degradation once secreted by the epithelium. For dis-
ease-associated TGFBIp containing FAS1-4 mutations, this
would lead to an increased turnover of the FAS1-4 species and
the generation of amyloidogenic core peptides prone to aggre-
gate formation. Interestingly, there appears to be a correlation
between specific mutations leading to LCD, time of onset
before deposit manifestations are observed, and how deeply
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Figure 5. HtrA1-generated fibrils are amyloid in nature. A, thioflavin T fluorescence as a function of time for 24 M LCD-linked FAS1-4 mutants preincubated
with and without 2 M HtrA1. A546D and A546D/P551Q both show some ThT fluorescence at the beginning of the assay, indicating nonnative structures for
these two mutants. Graphs are representatives of technical triplicates performed for each mutant. B, FTIR spectroscopy showing the distinct amyloid peak at
1627–1630 cm1 for all four samples preincubated with HtrA1. Graphs are averages of 64 technical measurements performed on each mutant. C, TEM
micrographs of samples showing linear fibers for samples incubated with HtrA1. HtrA1-deficient A546T and V624M samples show small nonamyloid aggre-
gates, whereas A546D and A546D/P551Q samples show larger nonamyloid aggregates, which likely play a role in the ThT signal observed for these mutants.
The scale bar is 100 nm. a.u., arbitary units.
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amyloid deposits extend into the corneal stroma, from the epi-
thelium toward the endothelium (29). This extension may
directly correlate with the severity of the destabilizing mutation
in the FAS1-4 domain of TGFBIp.
HtrA1 degradation product may inadvertently fuel the
progression of LCD
We have previously shown that the synthetic Tyr-571–Arg-
588 amyloidogenic core peptide can form fibrils (30), leaving
the possibility that digested FAS1-4 liberates the amyloidogenic
core region, allowing fibril formation. In our in vitro experi-
ments, HtrA1 was capable of digesting monomeric LCD-linked
mutant FAS1-4, leading to amyloid fibril formation by peptides
containing the amyloidogenic region (Figs. 3–5). Consequently,
HtrA1 may play an undesirable key role in the progression of
amyloid deposits in LCD caused by a mutation in FAS1-4 and
therefore may be a potential target for LCD treatment. We can-
not conclude whether the amyloidogenic region reported for
FAS1-1, Leu-110 –Glu-131 (31), accumulates upon HtrA1 pro-
teolysis, as we were unable to express and purify the FAS1-1
domain. HtrA1 accumulates in amyloid deposits caused by
both FAS1-1 and FAS1-4 mutations; however, FAS1-1 deposits
did not show the same pronounced accumulation of the Tyr-
571–Arg-588 amyloidogenic core region observed in deposits
of FAS1-4 mutations (12–15). These results suggest that other
amyloidogenic core regions in TGFBIp may constitute the amy-
loid deposits of FAS1-1–linked LCD. Altogether, our data sup-
port that HtrA1 unintentionally supplies building blocks to the
amyloid fibril in its attempt to remove misfolded and mutated
TGFBIp.
Changes in TGFBIp turnover lead to either GCD or LCD
We propose that the mutation-induced changes in the nor-
mal corneal TGFBIp turnover (Fig. 8A) govern the phenotypic
outcome (Fig. 8). Mutations associated with GCD lead to an
increase in structural and proteolytic stability and an increased
resistance to degradation by the proteolytic machinery in the
cornea. This resistance causes a build-up of mutant TGFBIp in
the cornea, eventually reaching a critical concentration and
driving the protein into insoluble aggregates (Fig. 8B). In con-
trast, mutations associated with LCD destabilize the structure
and increase TGFBIp turnover. In the case of FAS1-4 muta-
tions, this domain becomes a substrate of HtrA1 and hence
introduces an alternative turnover pathway (Fig. 8C). Whether
FAS1-1 and FAS1-4 mutations share the same mechanism of
protein aggregation is unclear. If so, one would expect all muta-
tions in FAS1-1 and FAS1-4 that cause the same phenotype to
be situated in close spatial proximity within the protein struc-
ture, thereby affecting the same local milieu of the protein.
However, this pattern is not observed in the TGFBIp crystal
structure (8). The disease-causing mutational hot-spot Arg-124
faces away from the FAS1-4 domain, and the many FAS1-4
mutations face away from Arg-124. Therefore, it is likely that
different mechanisms take place whether the mutation is situ-
Figure 6. HtrA1 is naturally present throughout the corneal stroma.
Human corneal sections were cut from the epithelium (Epi) toward the endo-
thelium (Endo) of 8-mm diameter corneal buttons (biological replicates, n 
4). Tissue sections were subjected to SDS-PAGE followed by immunoblotting
against HtrA1. HtrA1 was more or less uniformly distributed throughout the
corneal stroma and, hence, not recruited only upon amyloid formation. This
result implies that TGFBIp degradation products containing LCD-linked
mutations in the FAS1-4 domain can be turned over immediately once they
are formed.
Figure 7. FAS1-4 mutations lead to aberrant proteolytic processing of
TGFBIp in the human cornea. 2DE immunoblotting against TGFBIp in nor-
mal human tissue and LCD A546D and V624M corneal tissues is seen. Differ-
ential TGFBIp processing resulted in the detection of smaller amounts of deg-
radation products by an antiserum recognizing the FAS1-4 domain of TGFBIp
in LCD patient tissues. These data suggest an intensive turnover of mutated
FAS1-4 in the cornea of LCD patients, possibly involving HtrA1 proteolysis.
The pictures are representative of experimental replicates performed for each
tissue. Normal 1 and 2 are biological replicates.
HtrA1 proteolysis of TGFBIp
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ated in FAS1-1 or FAS1-4, but both result in the same pheno-
type. This interpretation is supported by our in vivo analyses of
mutated FAS1-1 and FAS1-4 deposits in LCD patient tissues
(12–15). Mutation in FAS1-4 caused the accumulation of a spe-
cific FAS1-4 polypeptide region, which was absent in the R124C
FAS1-1–linked LCD deposits. However, HtrA1 was associated
with both the FAS1-1– and FAS1-4 –related deposits, suggest-
ing common features and implying that a general treatment
directed at HtrA1 may be possible. Interestingly, others have
shown that a 22–amino acid residue region spanning residue
Arg-124 in FAS1-1 is capable of forming amyloid material in
vitro (31) and most likely represents the amyloidogenic core
region in FAS1-1–linked LCD patients. This possibility is fur-
ther supported by the observation of in vivo accumulation of
N-terminal degradation products of corneal TGFBIp in R124C
patient tissue (32). Of note, the suggested FAS1-1 amyloido-
genic core region becomes susceptible to fibrillation upon the
introduction of a mutation, whereas the amyloidogenic region
in FAS1-4 does not need any mutation to form amyloid mate-
rial. Therefore, a change in the extracellular environment and
not a mutation may be sufficient to cause TGFBIp aggregation,
as observed in Fuchs endothelial corneal dystrophy. Here,
TGFBIp is up-regulated and shown to be a part of the protein
aggregates observed in guttae formation in Fuchs endothelial
corneal dystrophy patients (33, 34).
Conclusion
Several studies point toward aberrant proteolytic processing
of TGFBIp as a crucial step toward the development of corneal
dystrophy, either by causing a shift in the normal TGFBIp turn-
Figure 8. Proposed mechanisms involved in TGFBI-linked corneal dystrophies. A, normal corneal TGFBIp turnover where TGFBIp is first cleaved in its
C-terminal, possibly by HtrA1. Then, it undergoes extensive N-terminal processing by the proteolytic machinery in the cornea, leading to FAS1-4 – containing
degradation products, which are cleared by an unknown mechanism. B, in GCD, the structural and proteolytic stability of TGFBIp increases, resulting in a slower
turnover of the protein. This slower turnover leads to a buildup of TGFBIp, which eventually forms amorphous aggregates upon reaching a critical concentra-
tion. C, in the case of LCD, the TGFBIp structure is compromised by a mutation that increases its turnover or leads to alternative degradation pathways. LCD
caused by FAS1-4 mutations allows the serine protease HtrA1 to turn over this domain, thereby liberating the amyloidogenic core region of TGFBIp. Upon
reaching a critical concentration, the TGFBIp core peptide starts to form amyloid aggregates.
HtrA1 proteolysis of TGFBIp
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over rate or by abnormal corneal TGFBIp degradation (12–15,
25, 32). Thus, targeting the proteolytic machinery involved in
TGFBIp processing may provide a way to prevent or delay the
disease progression of TGFBI-linked corneal dystrophy. The
serine protease HtrA1 has previously been associated with
in vivo TGFBIp deposits in LCD. In this study, we show that
TGFBIp is a substrate of HtrA1 and that mutations in TGFBIp
allow aberrant processing by HtrA1 that may inadvertently
promote amyloidogenesis in LCD.
Experimental procedures
Corneal tissue
Human postmortem corneal tissue (n  5; average age, 82
years old) and corneal LCD patient tissue that had been studied
previously (12, 13) were used with permission from the
Regional Committee for Scientific Medical Ethics, Denmark,
and according to the Declaration of Helsinki.
Recombinant FAS1-4 domain expression and purification
FAS1-4 WT and mutated variants (residues 502– 657 of
TGFBIp, Swiss-Prot accession number Q15582, with two addi-
tional amino acids Ala-Gly at the N terminus) were expressed
as N-terminally His-tagged SUMO-FAS1-4 fusion proteins in
the chemically competent Escherichia coli strain One Shot®
BL21(DE3) (Invitrogen) grown in lysogeny broth medium (Sig-
ma-Aldrich) containing 50 g/ml kanamycin (Sigma-Aldrich).
Expression of FAS1-4 was induced with 1 mM isopropyl -D-1-
thiogalactopyranoside(IPTG)(PanReacAppliChem)atanabsor-
bance of 0.4 – 0.7 at 600 nm. Three h after induction, cells were
harvested by centrifugation at 6000  g for 15 min and stored at
80 °C until further use.
The harvested cells were resuspended in 50 mM Tris-HCl,
500 mM NaCl, pH 7.6, containing a cOmplete, EDTA-Free Pro-
tease Inhibitor Mixture Tablet (Roche Diagnostics) and soni-
cated for 3  8 min at 70% amplitude with 0.5-s cycles while
kept on ice. Cell debris was removed by centrifugation for 15
min at 10,000  g, followed by 15 min of centrifugation at
25,000  g. The supernatant was filtered using a 0.22-m filter
and supplemented with 20 mM imidazole before being applied
to a 5-ml HisTrap HP column (GE Healthcare) equilibrated in
50 mM Tris-HCl, 500 mM NaCl, 20 mM imidazole, pH 7.6. The
protein was eluted using a stepwise gradient of 80 mM, 200 mM,
300 mM, 400 mM, and 500 mM imidazole, and protein fraction
purity was assessed by SDS-PAGE (SDS-PAGE). The purified
protein was dialyzed overnight at 4 °C into 50 mM Tris-HCl, 100
mM NaCl, pH 7.6, and the SUMO moiety was subsequently
cleaved off by the addition of 5 mM DTT and 4 unit/ml SUMO
Protease (Invitrogen) followed by incubation at room temper-
ature for 4 h. FAS1-4 protein was dialyzed into PBS and repu-
rified by nickel-chelating chromatography. Pure FAS1-4 pro-
tein was collected in the flow-through and stored at 80 °C.
Recombinant full-length TGFBIp expression and purification
Full-length TGFBIp variants were expressed in the human
cell line FreeStyleTM 293-F (Invitrogen) after transfection using
the polyethylenimine method. At 72 h after transfection, the
culture supernatant was collected by centrifugation for 2 min at
1000  g and incubated with 1 mM PMSF and 5 mM EDTA for
30 min before being dialyzed into buffer A (20 mM Tris-HCl, pH
7.5), followed by purification by affinity chromatography using
a 5 ml HiTrap Heparin HP column (GE Healthcare). A linear
gradient of buffer A to buffer B (20 mM Tris-HCl, 1 M NaCl, pH
7.5) was used to elute the protein. Selected fractions were ana-
lyzed by SDS-PAGE, and fractions containing TGFBIp were
pooled and dialyzed into buffer A. Subsequently, TGFBIp was
purified from the dialysate by anion-exchange chromatography
using a 5 ml HiTrap Q HP column (GE Healthcare) and eluted
with a linear gradient from buffer A to buffer B. Selected frac-
tions were analyzed by SDS-PAGE, and fractions containing
TGFBIp were pooled and dialyzed into PBS prior to storage at
80 °C.
Recombinant expression and purification of HtrA1
HtrA1 cDNA inserted into the pCMV6-XL4 vector using
NotI-NotI restriction sites was obtained from OriGene
(NM_002775). The translational and secreted product resulted
in the full-length HtrA1 serine protease (amino acid residues
23– 480) without any purification tags at its termini. HtrA1
plasmid was transfected using Fectin 293 (Life Technologies)
transfection reagent into Freestyle 293-F cells cultivated in
Freestyle 293 Expression Medium (Life Technologies) at a cell
density of 1  106 cells/ml. After incubation for 48 h, the cul-
ture supernatant was collected and dialyzed overnight at 4 °C
into 20 mM phosphate buffer, pH 7. The dialyzed medium was
subjected to cation exchange chromatography (HiTrap SP HP,
GE Healthcare) and developed using a 1 M NaCl gradient. The
HtrA1 fraction was subsequently dialyzed into 20 mM phos-
phate buffer, pH 7, at 4 °C and subjected to heparin chromatog-
raphy (HiTrap Heparin, GE Healthcare). The HtrA1 fraction
was pooled and dialyzed into PBS, pH 7.4, and the purity, con-
centration, and activity toward -casein were estimated and
tested by SDS-PAGE. A mock transfection and purification was
performed by transfecting cells without plasmid and by using
LC fractions corresponding to fractions that contained HtrA1
in the HtrA1 purification. LC-MS/MS analysis to identify
potential contaminating proteases was performed on the final
material of the mock purification and did not identify any con-
taminating proteases (data not shown).
HtrA1 proteolysis of soluble TGFBIp and FAS1-4
The activity of HtrA1 toward full-length TGFBIp variants
was tested by performing an HtrA1 titration series against a
fixed amount of full-length TGFBIp. To 0.25 g of full-length
TGFBIp was added 0, 31.5, 62.5, 125, 250, and 1000 ng of HtrA1,
separately, and the mixtures were incubated overnight at 37 °C
before being inhibited by 2 mM PMSF. A control with the high-
est amount of HtrA1 alone was included. Samples were sub-
jected to SDS-PAGE followed by the detection and quantifica-
tion of TGFBIp by immunoblotting using a rabbit polyclonal
antibody against the TGFBIp peptide 571-YHIGDEILVSGGI-
GALVR-588 (EZBiolab) and a Cy3-labeled secondary antibody
(Sigma-Aldrich). All samples were analyzed in triplicate. Com-
parison between the WT and mutant titration series was per-
formed by normalizing each titration point to the sample with-
out HtrA1 for a given titration series.
HtrA1 proteolysis of TGFBIp
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To test the activity of HtrA1 toward FAS1-4 variants, an
HtrA1 titration series was performed against a fixed amount of
FAS1-4. To 2 g of FAS1-4 was added 0, 0.125, 0.25, 0.5, and 1
g of HtrA1, separately, and incubated overnight at 37 °C
before being inhibited by 2 mM PMSF. A control with the high-
est amount of HtrA1 alone was included. Samples were sub-
jected to SDS-PAGE, and densitometry of the bands was per-
formed on a FluorChem Q scanner using the AlphaView
software (ProteinSimple). All samples were analyzed in tripli-
cate and normalized to the sample without HtrA1.
Furthermore, an additional HtrA1 digest of LCD-associated
FAS1-4 mutants using the highest protease concentration was
included and subjected to LC-MS/MS analysis. HtrA1 cleavage
sites observed more than eight times were compared between
FAS1-4 variants.
LC-MS/MS analysis
Samples for MS were analyzed by nanoflow LC-tandem MS
(LC-MS/MS) using an Easy-nLC II system (Thermo Scientific)
coupled directly to a TripleTOF 5600 mass spectrometer (AB
Sciex) operated under Analyst TF 1.6.0 control. Samples were
loaded on a 0.1  20 mm 3-m C18 trap column and a 0.075 
150 mm 3-m C18 analytical column, both pulled and packed
in-house. Peptides were eluted and electrosprayed directly into
the mass spectrometer using a 20 min gradient from 5– 40%
acetonitrile in 0.1% acetic acid at a flow rate of 250 nl/min. Data
were acquired using an ion spray voltage of 2.3 kV, a curtain gas
of 30, and an interface heater temperature of 150 °C. For
information-dependent acquisition, survey scans were acquired in
250 ms, and as many as 25 product ion scans were collected if
exceeding a threshold of 150 counts per second and with a 2 to
5 charge-state. A sweep collision energy setting of 35  15 eV
was applied to all precursor ions for collision-induced dissociation.
No dynamic exclusion was applied.
MS database search
MS Raw data were converted to mgf format using AB SCIEX
MS Data Converter beta 1.1 (AB Sciex) and the “proteinpilot
MGF” parameters and searched using an in-house Mascot
search engine (Matrix Science, London, UK; version: 2.3.02)
against the Swiss-Prot database (version: 2012_05). No enzyme
was selected, and missed cleavage was set to 0. No fixed modi-
fications were added. Instead, the oxidation of methionine and
proline were included as variable modifications. The MS toler-
ance and MS/MS tolerance were 10 ppm and 0.2 Da, respec-
tively, and an ESI-QUAD-TOF system was set as the instru-
ment used. All data sets were searched using a p value  0.01,
and peptides with an ion score lower than 30 were rejected. All
searched data were imported to and processed in MS Data
Miner (version 2.0) (35).
Proteolysis of FAS1-4 in amyloid formation
The propensity for HtrA1-generated FAS1-4 peptides to
form aggregates was investigated by incubating 24 M (32 g)
of mutant FAS1-4 (A546D, A546D/P551Q, A546T, and
V624M) with or without 2 M (8 g) HtrA1 in PBS, pH 7.4, for
21 h at 37 °C. The FAS1-4 samples with and without prior
HtrA1 digestion were subsequently incubated at 37 °C with
double orbital shaking for 2 min at 500 rpm every 20 min. The
fibrillation was carried out in triplicate in the presence of ThT
to monitor fluorescence over time (described in detail below).
All samples were divided into pellet and supernatant fractions
by 40,000  g centrifugation followed by FTIR, TEM, and LC-
MS/MS. The identified TGFBIp peptides were divided into bins
of 10 –amino acid residues throughout the sequence, and each
fraction was summed and plotted as an intensity (spectral
count).
ThT, FTIR, and TEM characterization
To verify the nature of the HtrA1-generated fibrils as amy-
loid, thioflavin T fluorescence was recorded as a function of
time. FAS1-4 protein was incubated with and without the pres-
ence of HtrA1 using a final ThT concentration of 40 M (Ex 450
nm, Em 480 nm). The samples were then further analyzed by
FTIR spectroscopy on a Tensor 27 (Bruker) FTIR spectropho-
tometer equipped with a DTGS Mid-IR detector and a Golden
Gate single-reflection diamond-attenuated total reflectance
cell (Specac). Samples were placed on the ATR crystal and dried
using dry nitrogen. Spectra were recorded from 4000 –1000
cm1 using a resolution of 2 cm1 and 64 accumulations. The
data were corrected for background and atmospheric interfer-
ence and normalized to the peak intensity. Finally, TEM micro-
graphs were taken for all samples. Five l of sample were
mounted on 400 mesh carbon-coated, glow-discharged nickel
grids for 1 min, stained with 1 drop of phosphotungstic acid
(PTA), pH  7.0 and blotted dry on filter paper. EM was per-
formed on a JEOL-1010 electron microscope (JEOL, Tokyo,
Japan) operated at 60 keV. The microscope was coupled to an
electron-sensitive CDC camera (KeenView, Olympus Soft
Imaging Solutions GmbH, Münster, Germany). A grid-size rep-
lica (2160 lines/mm) was used for size determination.
2DE of human corneal tissue
Human LCD and WT corneal tissue samples were lyophi-
lized for 6 h before homogenization in liquid nitrogen to gen-
erate corneal powder. The corneal powder was then subjected
to 2DE lysis buffer followed by 2DE using a pH 4 –7 strip and
10% gels and was immunoblotted. Rabbit antisera recognizing
TGFBIp were used as the primary antibody at a 1:5000 dilution
in 2% skimmed milk/TBS-T, and goat anti-rabbit HRP-conju-
gated antibody was used as the secondary antibody at a 1:10,000
dilution in 2% skimmed milk.
Stromal HtrA1 distribution
Eight mm central postmortem human corneal buttons from
three individuals were cut into sections of 50 m from the epi-
thelium toward the endothelium. Nine sections throughout the
corneal stroma from each cornea were boiled in SDS sample
buffer, leaving out the two outermost corneal cell layers. The
samples were subjected to SDS-PAGE, followed by immuno-
blotting using HtrA1 antiserum. Blots were developed using
the FluorChem Q scanner and the AlphaView software
(ProteinSimple).
LC-SRM analysis of TGFBIp terminal truncations
All but one of the expressed and purified TGFBIp isoforms
resulted in two bands when analyzed by SDS-PAGE, most likely
HtrA1 proteolysis of TGFBIp
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as a consequence of terminal truncation. To clarify at which
terminal truncation occurs, a target SRM-MS–based analysis was
performed to map tryptic peptides along the whole TGFBIp
protein. The SRM assay was optimized using Skyline v.3.1.0
(36), in which 25 peptides with four transitions each were mon-
itored. Stable isotope-labeled synthetic peptides (SpikeTides,
JPT Peptide Technologies, Berlin, Germany) were used for
assay development and as spike-in standard peptides in the in-
gel digested TGFBIp samples. LC-SRM was performed using an
EASY-nano LC (Thermo Scientific, Waltham, MA) connected
in-line with a QTRAP 6500 (AB Sciex, Framingham, MA). Pep-
tide samples were injected and trapped on a C18 precolumn (5
m, 2 cm  100 m I.D., packed in-house), followed by elution
to and separation on a 15-cm analytical column (75 m I.D.,
packed in-house with RP ReproSil-Pur C18-AQ 3 m resin (Dr.
Maisch GmbH, Ammerbuch-Entringen, Germany) using a flow
rate of 250 nl/min and a 20-min 5–35% B gradient (A solvent;
0.1% formic acid, B solvent; 0.1% formic acid and 100% aceto-
nitrile). The SRM assay was run as a scheduled method using a
3-min window. The raw SRM data were imported to Skyline to
obtain the L/H ratio of the tryptic TGFBIp peptides and subse-
quently exported to Excel. The summed intensities of four
internal peptides of TGFBIp (77-STVISYECCPGYEK-90, 173-
YHMVGR-178, 180-VLTDELK-186, and 220-ADHHATNGV-
VHLIDK-234) were used to normalize the upper and lower
band intensities before determining the ratios of the N-termi-
nal (28-SPYQLVLQHSR-38) and C-terminal (670-LAPVYQK-
676) peptides between the lower and upper band. The R124H
full-length TGFBIp mutant migrated as one band and was nor-
malized to the WT full-length TGFBIp upper band.
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